老师让我了一夜视频-sm羞辱调教视频网站-日韩精品乱码久久久久久-香蕉久久久久久-东北孕妇疯狂作爱-少妇高潮一区二区三区99小说-国产乱码精品一区二区三区五月婷-午夜视频91-男男把屁股眼子玩坏了bl,一女被多男玩喷潮视频,在情趣店被调教成yin娃的小说,贺朝用笔把谢俞

Stock(600222)Hot line:010-83057670

News

Understand the latest news of Leadingpharm

Chairman Wallace Tao of Leadingpharm was Awarded the Title of Top 100 Figures in Promoting High Quality Development of the Medical and Health Industry

Release time:2023-11-09

On November 8, at the second Mount Taishan Pharmaceutical Forum hosted by the All-China Federation of Industry and Commerce Chamber of Medicine and Pharmaceutical Industry and the Mount Taishan Pharmaceutical Forum Organizing Committee, Mr. Wallace Tao, the Chairman of, won the award of Top 100 Figures in Promoting High Quality Development of the Medical and Health Industry.
 

As the founder of Leadingpharm, Chairman Wallace Tao has been committed to the development and innovation of the pharmaceutical and health industry since the establishment of Leadingpharm in 2005. He is the first to innovate Leadingpharm CXO Whole Industry Chain Ecosystem, make Leadingpharm a full partner in new drug creation, accelerate the process of drug listing and transformation, and promote the transformation and upgrading of the pharmaceutical industry. The award of Top 100 Figures in Promoting High Quality Development of the Medical and Health Industry for 2022-2023 is a high recognition of Mr. Tao's long-term investment and contribution to the medical and health industry.

 

At the meeting, the sponsor also awarded the Star Enterprise Award of the second Mount Taishan Pharmaceutical Forum for the Leadingpharm. As a leading pharmaceutical R&D enterprise, Leadingpharm has been awarded honors such as Top 10 Chinese Pharmaceutical R&D Companies by the All-China Federation of Industry and Commerce for many consecutive years. This award once again proves Leadingpharm's leading position and influence in the industry. Looking ahead to the future, Leadingpharm will continue to devote itself to technological innovation and product research and development, improve clinical service levels, accelerate the transformation of innovative achievements, and continuously enhance the core competitiveness of the enterprise. At the same time, we will actively fulfill our social responsibility and make greater contributions to promoting the high-quality development of the pharmaceutical and health industry.

轉載聲明:未經本網或本網權利人授權,不得轉載、摘編或利用其他方式使用上述作品。已經本網或本網權利人授權使用作品的,應在授權范圍內使用,并注明“來源:新領先醫藥科技”。

Recommend